Literature DB >> 16084324

The prognosis of mixed connective tissue disease.

Ingrid E Lundberg1.   

Abstract

The prognosis for patients who have mixed connective tissue disease (MCTD) varies from a benign course to severe progressive disease. In approximately one third of patients the clinical symptoms go into long-term remission and the anti-U1 small nuclear ribonucleoprotein antibodies disappear. One third of patients have a severe, progressive disease course. Persistent morbidity often is attributable to arthritis, easy fatiguability, and dyspnea on exertion. The most severe clinical manifestation is pulmonary hypertension which contributes to premature death in patients who have MCTD. Pulmonary hypertension is associated with proliferative vascular abnormalities that involve small pulmonary vessels, rather than interstitial lung disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16084324     DOI: 10.1016/j.rdc.2005.04.005

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  9 in total

Review 1.  Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions.

Authors:  Silvia Bellando-Randone; Marco Matucci-Cerinic
Journal:  Curr Rheumatol Rep       Date:  2017-09-18       Impact factor: 4.592

2.  Following leads: connecting dysphagia to mixed connective tissue disease.

Authors:  Rita de Sousa Gameiro; Ana Isabel Alves Reis; Ana Cristina Grilo; Carla Noronha
Journal:  BMJ Case Rep       Date:  2018-03-05

Review 3.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

4.  Sarcoidosis in patients with mixed connective tissue disease: clinical, genetic, serological and histological observations.

Authors:  Peter Szodoray; Zoltan Szollosi; Edit Gyimesi; Istvan Takacs; Gabriella Mekkel; Judit Vegh; Anna Szilagyi; Margit Zeher; Gyula Szegedi; Edit Bodolay
Journal:  Rheumatol Int       Date:  2008-01-15       Impact factor: 2.631

5.  Disease evolution in mixed connective tissue disease: results from a long-term nationwide prospective cohort study.

Authors:  Silje Reiseter; Ragnar Gunnarsson; Jukka Corander; Joanna Haydon; May Brit Lund; Trond Mogens Aaløkken; Eli Taraldsrud; Siri Opsahl Hetlevik; Øyvind Molberg
Journal:  Arthritis Res Ther       Date:  2017-12-21       Impact factor: 5.156

Review 6.  Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.

Authors:  So-My Koo; Soo-Taek Uh
Journal:  Korean J Intern Med       Date:  2017-06-30       Impact factor: 2.884

7.  Mixed connective tissue disease: state of the art on clinical practice guidelines.

Authors:  Benjamin Chaigne; Carlo Alberto Scirè; Rosaria Talarico; Tobias Alexander; Zahir Amoura; Tadej Avcin; Lorenzo Beretta; Andrea Doria; Aurelien Guffroy; Vera Guimarães; Éric Hachulla; Thomas Krieg; David Launay; Gemma Lepri; Pia Moinzadeh; Ulf Müller-Ladner; Simona Rednic; Ana Rodrigues; Sander W Tas; Ronald F van Vollenhoven; Ana Vieira; Stefano Bombardieri; João Eurico Fonseca; Ilaria Galetti; Matthias Schneider; Vanessa Smith; Maurizio Cutolo; Marta Mosca; Rebecca Fischer-Betz
Journal:  RMD Open       Date:  2018-10-18

Review 8.  "Mixed connective tissue disease": a condition in search of an identity.

Authors:  Marta R Alves; David A Isenberg
Journal:  Clin Exp Med       Date:  2020-03-04       Impact factor: 3.984

9.  Massive Hemorrhagic Pericardial Effusion With Cardiac Tamponade as Initial Manifestation of Mixed Connective Tissue Disease.

Authors:  Ashraf Abugroun; Osama Hallak; Fatima Ahmed; Safwan Gaznabi
Journal:  Cardiol Res       Date:  2018-02-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.